1. Home
  2. ATAI

as 06-13-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.

Founded: 2018 Country:
Germany
Germany
Employees: N/A City: BERLIN
Market Cap: 221.0M IPO Year: 2021
Target Price: $12.00 AVG Volume (30 days): 1.4M
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.24 EPS Growth: N/A
52 Week Low/High: $1.02 - $2.85 Next Earning Date: 08-08-2024
Revenue: $277,000 Revenue Growth: 2.97%
Revenue Growth (this year): -18.79% Revenue Growth (next year): N/A

ATAI Daily Stock ML Predictions

Stock Insider Trading Activity of ATAI Life Sciences N.V. (ATAI)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Johnson Anne Nagengast ATAI Chief Financial Officer Apr 2 '24 Sell $1.85 27,410 $50,708.50 73,590 SEC Form 4

Share on Social Networks: